| Title | Management of Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis With Inhaled Fluticasone Propionate/Salmeterol (ADVAIR DISKUS) 250/50: Results of a Patient Experience Trial. | | Author(s) | Stoloff S, Samuels S, Kerney D, Brown CP | | Institution | The University of Nevada School of Medicine, Reno, Nevada. | | Source | MedGenMed 2006; 8(1):86. | | Abstract | Context: Chronic obstructive pulmonary disease (COPD) is recognized as a major healthcare problem in the United States and around the world.
Objective: This survey regarding initial experience in patients with COPD collected feedback about newly initiated therapy with fluticasone propionate/salmeterol (FSC; ADVAIR DISKUS).
Design: Three telephone surveys were conducted; Survey 1 prior to initiating therapy with FSC 250/50, and Surveys 2 and 3 at 2 weeks and 30 days after initiating therapy with FSC 250/50, respectively.
Setting: One thousand primary care physicians recruited outpatients into the trial.
Patients: Patients were either newly diagnosed with COPD associated with chronic bronchitis or were still experiencing breathing difficulties on an anticholinergic medication.
Interventions: Patients initiated FSC 250/50 and received a 1-month supply of FSC 250/50 with an albuterol inhaler for rescue use. Main Outcome Measures: Outcome measures were patient perceptions of satisfaction, compliance, and convenience and changes in breathing on 1 (negative) to 9 (positive) point scales.
Results: Five hundred sixteen patients completed all 3 surveys. The mean age was 61 years, 63% were female, and 62% had been diagnosed with COPD associated with chronic bronchitis for 3 years or less ( Table 1 ).
Conclusion: Patients reported high satisfaction, compliance, and convenience with FSC 250/50 within 2 weeks of initiating therapy, all maintained over the trial period. Additionally, patients had positive changes in breathing, including improvements in the ability to breathe upon awakening in the morning. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 16915216 |
|
